

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **February 2017**

Commission File Number: **001-36187**

**EVOGENE LTD.**

(Translation of Registrant's Name into English)

**13 Gad Feinstein Street  
Park Rehovot P.O.B 2100  
Rehovot 7612002 Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_

---

## CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 A Slide Presentation for Investors – February 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.  
(Registrant)

Date: February 6, 2017

By: /s/ Alex Taskar

\_\_\_\_\_  
Alex Taskar  
Chief Financial Officer

EXHIBIT INDEX

<u>EXHIBIT NO.</u>	<u>DESCRIPTION</u>
99.1	A Slide Presentation for Investors – February 2017.



## Introduction to Evogene

Ofer Haviv, President & CEO

February 2017



## Safe Harbor statement

---

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.


The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.



## Table of contents

- **Introduction**
- Our technology
- Applications and product programs
- Summary of investment highlights

# Introducing Evogene



## ► We are...

A leading biotechnology company for the improvement of crop productivity and performance, addressing the world's increasing demand for food, feed and fuel

## Farmer's main inputs



### ► Farmer's target – maximize profit

- ↑ Increase crop yield
- ↓ Reduce losses from stresses
- ↓ Minimize input expenses



# The opportunity

## A dire need for innovation




### Seeds - \$37B<sup>1</sup>

- Crops' full yield potential - yet to be captured
- Insect control - resistance to available commercial traits



### Ag-Chemicals - \$56B<sup>2</sup>

- Extra yield of up to 60% - significant potential yet to be captured
- Resistance to available commercial solutions



### Ag-Biologicals - \$3B<sup>3</sup>

- Emerging as promising tool to drive productivity – mainly due to microbiome & data revolution
- Stability limits applicability of existing products



<sup>1</sup> Source: Phillips McDougall, 2016


<sup>2</sup> Source: Phillips McDougall, 2015

<sup>3</sup> Source: Research & Markets, 2016

## Evogene 'at a glance'



- **An innovative, predictive discovery technology** - applied to identify:
  - Genetic elements for improved seeds
  - Chemical compounds for innovative Ag-Chemicals
  - Microbes for novel Ag-Biologicals
- **Strategic collaborations with world-leading agriculture companies** - including BASF, Bayer, DuPont, Monsanto, Syngenta
- **Revenue model** - based on licensing agreements, which typically include three main revenue streams:
  - R&D payments - short term
  - Milestone payments - mid term
  - Royalties from product sales - longer term
- **Financial fundamentals** -
  - Cash position - \$93 million (September 30<sup>th</sup>, 2016)
  - Projected cash use for 2016 - ~\$15 million
  - Listed on TASE (2007) and NASDAQ (2013)



# Our revenue & business models



## Collaboration timeline



## Revenue model

<b>RD</b>	R&D payments	▪ R&D funding by partner
<b>M</b>	Milestone fees	▪ Additional payments received upon achieving predetermined objectives
<b>R</b>	Royalties	▪ Percentage of product sales by partner


## Business model

<b>E</b>	Early collaboration model	▪ Collaboration <u>prior</u> to initiating product discovery and development activity
<b>L<sub>1,2</sub></b>	Late collaboration models	▪ Collaboration <u>following</u> internal product discovery and early development

# Value creation per product program



## Collaboration timeline






## Table of contents

- Introduction
- **Our technology**
- Applications and product programs
- Summary of investment highlights

# Technology platform



# Plant validation systems

Providing proof for our predictions




# Technology platform

## Implementation pathways



### Platform outputs:

Basis for development of innovative products






## Table of contents

- Introduction
- Our technology
- **Applications and product programs**
- Summary of investment highlights


# Application pathways

## Platform outputs:

Basis for development of innovative products



# Improved seeds - market and unmet needs



**Broad commercial potential for bringing 'breakthrough' traits to the seed market**

\* Source: Phillips McDougall, 2015

# Improved seeds - activities and achievements



## Overview

- **Product trait programs** - focus on corn, soy, wheat, cotton and canola
  - Yield and abiotic stress – since 2004
  - Disease resistance - since 2007
  - Insect resistance – since 2014
- **Main achievements** -
  - Most advanced gene in Phase II of development
  - Collaborations with industry leaders
  - Strong IP portfolio - over 4000 genes under patent protection
  - Over 1000 genes under target crop validation by partners

### Traits



### Partners



## Example: Monsanto-Evogene collaboration

- **Collaboration period** - 8 years
- **Objective** - improved seeds via biotechnology
  - **Crops** - Corn, soybean, cotton, canola
  - **Traits** -
    - Yield, drought tolerance, fertilizer utilization
    - Insect resistance – Fusarium resistance in corn
- **Key terms** -
  - R&D and up-front payments - total c.\$68M
  - Milestone payments + royalties from sales
  - \$30M equity investment (including \$12M in IPO)



# Improved seeds - selected results



## MONSANTO collaboration

Yield

Abiotic stresses

**Genes demonstrated potential to achieve yield enhancement in target crops**

Evogene Discloses Positive Results in Yield Improvement Collaboration with Monsanto Utilizing Novel 'Trait-First' Methodology

February 23rd, 2016

Results, obtained for a set of Evogene discovered genes, in testing by its key collaborator, Monsanto, demonstrate potential to achieve yield enhancement in corn and soybean.

Rehovot, Israel – February 23<sup>rd</sup>, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries announced today **positive results from the testing of a set of the Company's discovered genes in corn and soybeans** conducted this past season by its key collaborator, Monsanto. These are the first results for genes discovered and tested pursuant to a 'Trait-First' methodology implemented in the frame of the parties' on-going, multi-year collaboration which focuses on yield enhancement and abiotic stress resistance.



**Additional optimization & development towards phase 2**

## Internal program


Insect resistance  
(internal program)

**Novel toxins showed activity against Lepidoptera and Coleopteran insects**

EVO50010076 – Fall Army Worm

EVO50010076


No treatment



EVO50010061 – Soybean Looper


EVO50010061

No treatment



**Further optimization and validation in plants towards licensing agreement**


# Improved seeds - upcoming value drivers



# Application pathways

## Platform outputs:

Basis for development of innovative products




# Innovative Ag-Chemicals - market and unmet needs




~\$37B\* in 2015

Innovation potential




\* Source: Phillips McDougall, 2015

Dire need for novel herbicides due to increasing resistance



Glyphosate - leading herbicide with >\$5B sales, yet broadly increasing weed resistance



Source - International Survey of Herbicide Resistant Weeds, [www.weedscience.org/graphs/soagraph.aspx](http://www.weedscience.org/graphs/soagraph.aspx) (2013)

Key challenge - finding the next generation of novel herbicide

# Innovative Ag-Chemicals - activities & achievements




## Overview

### Product programs –

- Novel herbicides with new Mode of Action (MOA) - since 2013

### Main achievements –

- Strategic collaboration with BASF (signed in 2015)
- Discovery and validation in plants of several novel herbicide targets
- Tens of discovered small molecules showing potential as active ingredient in novel herbicide



## Example: BASF-Evogene collaboration

### Collaboration period - 3 years

### Objective - herbicides with new MOA

### Activities -

- Evogene to identify novel targets and target-linked chemicals candidates
- BASF to screen & validate the candidate chemicals and further develop successful candidates towards commercial products



# Innovative Ag-Chemicals - selected results

## Targets successfully validated in plants

### Evogene Announces Discovery and Validation of Novel Plant Targets for Herbicides

July 29th, 2015


- Newly discovered targets predicted to represent new modes of action

Rehovot, Israel – July 29, 2015 – Evogene Ltd. (NYSE: TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, announced today the discovery and successful validation in plants of the first set of novel plant targets, representing a key milestone in its product program for new chemical herbicides. Targets for herbicides are vital plant macro-molecules taking part in essential biological processes in weeds ('modes of action'). The Evogene discovered targets will now be the subject of a unique methodology for the discovery of chemical molecules that can inhibit their functionality, resulting in weed death. These chemical molecules would then serve as the basis for the development of the active

### Normal target activity - healthy plant



### Target inhibition - dying plant




Path forward


Advancement of targets and chemical hits – optimization and additional plant testing

## Chemicals displayed herbicide activity against weeds

Commercial herbicide (positive control)



EVO AG1345\*




No treatment (negative control)



\*Prior to optimization

\* Results from Evogene's internal activity


# Innovative Ag-Chemicals - upcoming value drivers




# Application pathways

## Platform outputs:

Basis for development of innovative products



# Novel Ag-Biologicals - market and potential



# Novel Ag-Biologicals - activities and achievements



## Overview

### ■ Product programs -

- Bio-stimulant (mainly yield and abiotic stress) in corn, soy and wheat – since 2015

### ■ Main achievements -

- 10's of microbes showing consistent improvement of yield traits in greenhouse and field
- Establishment infrastructure for product research and development - computational, tailored OMIC experiments, plant assays, formulation and fermentation
- 20K isolated microbes from unique sourcing samples, with > 10K sequenced genomes

### Crops




X

### Product

Bio-stimulant

## Internal Bio-stimulant discovery & development program

- **Internal Evogene program** - including downstream activity
- **License out to partner** – late collaboration model
- **Expected time to product** - ~5 years



# Novel Ag-Biologicals - selected results



## 10's of microbial Hits displaying positive results in corn field trials


### Evogene Announces Positive Field Trial Results in Ag-biologicals Program

November 16th, 2016

- Candidate microbial strains demonstrate positive efficacy and stability results in first year of field testing in corn under drought conditions

**Rehovot, Israel – November 16, 2016** – Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and fuel industries, announced today positive field trial results conducted in Israel from its Ag-biologicals program, which is currently focused on the development of Bio-stimulant products. In these tests, candidate microbial strains identified and predicted by Evogene for their ability to improve corn resistance to drought conditions, yielded positive efficacy and stability results in the first year of field testing.


*Example: EVO-0685 – improved ear size and weight at harvest resulted with **17% increase of yield per plant***



Path forward

**Combination of microbial hits, additional testing along with product development activities (upscale, fermentation & formulation)**

# Novel Ag-Biologicals - upcoming value drivers





## Table of contents

- Introduction
- Our technology
- Applications and product programs
- **Summary of investment highlights**

## Investment highlights

---



- 1 Unique technology platform, combining expertise in plant science and cutting-edge computational tools
- 2 Engine for next generation product development targeting multi-billion dollar ag markets
- 3 Innovation partner of choice for industry leaders
- 4 Diversified product portfolio with multiple paths to milestone payments and royalties from commercialization
- 5 Strong balance sheet



Thank you.

**Contact:**  
[investors@evogene.com](mailto:investors@evogene.com)  
T: +972 8 931 1964

---

---